Physician profile
Jack L Arbiser
NPI 1710092648
$7,634.73
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $6,510 · 2022: $117 · 2023: $226 · 2024: $391 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $80.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.73 |
| Education | $80.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $6,763.30 | 2019-2022 | |
| Genzyme Corporation | $264.16 | 2023-2025 | |
| Janssen Biotech, INC. | $215.46 | 2023-2025 | Tremfya, Remicade, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $135.07 | 2023-2024 | Zoryve |
| Incyte Corporation | $56.52 | 2023-2024 | Opzelura |
| Pfizer INC. | $38.71 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $31.39 | 2025 | |
| Verrica Pharmaceuticals INC. | $29.76 | 2023 | Ycanth |
| Krystal Biotech INC | $27.80 | 2024 | Vyjuvek |
| Amgen INC. | $24.01 | 2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $17.09 | 2023 | Ilumya |
| Galderma Laboratories, L.P. | $16.65 | 2025 | |
| Mayne Pharma Commercial LLC | $14.81 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Arbiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.